Mesothelioma Information   SUBMIT

ecancer's Gordon McVie provides a roundup of the main points of discussion from ESMO 2014. He mentions the following studies: Adding cediranib to chemo improves PFS for metastatic cervical cancer Anamorelin improves appetite and body mass in non-small cell-lung cancer with cancer anorexia cachexia Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy PD-L1 protein a possible immunotherapy target in mesothelioma Second-line afatinib significantly improves PFS in metastatic head and neck cancer PIK3CA mutations blunt benefit of anti-HER2 drugs in breast cancer Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer HER2 inhibition shows promise in HER2-positive non-small cell lung cancer Scan may identify lung cancer patients who will benefit from folate-targeted drug Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma Click here to read the conference report.